KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 49-57

  Sihto, Harri ^a   Sarlomo Rikala, Maarit ^a   Tynninen, Olli ^a   Tanner, Minna ^a   Andersson, Leif C ^a   Franssila, Kaarle ^a   Nupponen, Nina N ^a   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

AMINO ACID SEQUENCE; ANEUPLOIDY; ARTICLE; CHROMOSOME 4; CONTROLLED STUDY; DRUG TARGETING; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STATISTICAL ANALYSIS; TESTIS CARCINOMA; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENETICS; MALE; MUTATION; POLYMERASE CHAIN REACTION; SMALL CELL CARCINOMA; TERATOCARCINOMA; TESTIS TUMOR;

ANEUPLOIDY; CARCINOMA, SMALL CELL; CHROMOSOMES, HUMAN, PAIR 4; EXONS; GASTROINTESTINAL NEOPLASMS; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MUTATION; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TERATOCARCINOMA; TESTICULAR NEOPLASMS;

EID: 16644381251     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.093     Document Type: Article

References (52)

1. Capdeville R, Buchdunger E, Zimmermann J, et al: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502, 2002
2. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
3. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002
4. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003
5. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586-3591, 2002
6. Mace J, Biermann JS, Sondak V, et al: Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373-2379, 2002
7. Joensuu H, Roberts P, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001
8. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
9. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al: CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728-734, 1998
10. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002
11. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
12. Hirota S, Ohashi A, Nishida T, et al: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125:660-667, 2003
13. Andre C, Martin E, Cornu M, et al: Genomic organization of the human c-kit gene: Evolution of the receptor tyrosine kinase subclass III. Oncogene 7:685-691, 1992
14. Spritz RA, Strunk KM, Lee S-T, et al: A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 22:431-436, 1994
15. Qiu F, Ray P, Brown K, et al: Primary structure of c-kit. Relationship with the CSF-1/PDGF receptor kinase family-Oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7:1003-1011, 1988
16. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
17. Furitsu T, Tsujimura T, Tono T, et al: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736-1744, 1993
18. Nagata H, Worobec A, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560-10564, 1995
19. Longley JB, Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96:1609-1614, 1999
20. Tian Q, Frierson HF, Krystal GW, et al: Activating c-kit mutations in human germ cell tumors. Am J Pathol 154:1643-1647, 1999
21. Przygodzki RM, Hubbs AE, Zhao F-Q, et al: Primary mediastinal seminomas: Evidence of single and multiple KIT mutations. Lab Invest 82:1369-1375, 2002
22. Sakuma Y, Sakurai S, Oguni S, et al: Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 94:486-491, 2003
23. Kemmer K, Corless CL, Fletcher JA, et al: KIT mutations are common in testicular seminomas. Am J Pathol 164:305-313, 2004
24. Tsuura Y, Hiraki H, Watanabe K, et al: Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: Immunohistochemical study of formalin-fixed, paraffin-embedded tissues. Virchows Arch 424:135-141, 1994
25. O'Donovan MC, Oefner PJ, Roberts SC, et al: Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics 52:44-49, 1998
26. Han S, Cooper DN, Upadhyaya M: Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 109:487-497, 2001
27. Looijenga LH, de Leeuw H, van Oorschot M, et al: Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 63:7674-7678, 2003
28. Joensuu H, Isola J, Lundin M, et al: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 9:923-930, 2003
29. Hyytinen E, Visakorpi T, Kallioniemi A, et al: Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization: Cytometry 16:93-99, 1994
30. Xiao W, Oefner PJ: Denaturing high-performance liquid chromatography: A review. Hum Mutat 17:439-474, 2001
31. Lasota J, Jasinski M, Sarlomo-Rikala M, et al: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53-60, 1999
32. Corless CL, McGreevey L, Haley A, et al: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572, 2002
33. Rubin BP, Singer S, Tsao C, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121, 2001
34. Hirota S, Nishida T, Isozaki K, et al: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193:505-510, 2001
35. Burger H, den Bakker MA, Stoter G, et al: Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39:793-799, 2003
36. Yeng YM, Lin CY, Hsu HC: Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154:107-111, 2000
37. Holst VA, Marshall CE, Moskaluk CA, et al: KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12:956-960, 1999
38. Hongyo T, Li T, Syaifundin M, et al: Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 60:2345-2347, 2000
39. Buttner C, Henz BM, Welker P, et al: Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol 111:1227-1231, 1998
40. Pietras K, Sjöblom T, Rubin K, et al: PDGF receptors as cancer drug targets. Cancer Cell 3:439-443, 2003
41. Clarke ID, Dirks PB: A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 22:722-733, 2003
42. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
43. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
44. Kinoshita K, Hirota S, Isozaki K, et al: Absence of c-kit mutations in gastrointestinal stromal tumours from neurofibromatosis type I patients. J Pathol 202:80-85, 2004
45. Apte SM, Fan D, Killion JJ, et al: Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10:897-908, 2004
46. Hwang RF, Yokoi K, Bucana CD, et al: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9:6534-6544, 2003
47. Beppu K, Jaboine J, Merchant MS, et al: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96:46-55, 2004
48. Ebos JM, Tran J, Master Z, et al: Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 1:89-95, 2002
49. Dudley A, Gilbert RE, Thomas D, et al: STI-571 inhibits in vitro angiogenesis. Biochem Biophys Res Commun 310:135-142, 2003
50. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002
51. Pietras K, Stumm M, Hubert M, et al: STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9:3779-3787, 2003
52. Kindler T, Breitenbuecher F, Marx A, et al: The efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 103:3644-3654, 2004